Talquetamab (JNJ-64407564) is a first-in-class duobody IgG4 PAA antibody that binds to GPRC5D and CD3 to redirect T cells for T cell mediated lysis of GPRC5D positive MM cells [95]. Here, GPRC5D is linked to Miyoshi myopathy.